Rutgers Cancer Institute of New Jersey ( Site 0033)

New Brunswick, New Jersey 08903-2681

2 studies enrolling now · 4 studies all time

What they study most

Breast Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer Metastatic, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Studies at this site

• A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) — Recruiting now
• Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) — Recruiting now
• A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) — Recruiting now
• Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) — Recruiting now